Mutation of Hepatitis B Virus Precore/basal Core Promoter in 234 Patients with Chronic Hepatitis

白丽,王琳,李乐,孟玉华,万芃瑾,刘晓红,陈雪源,张玲霞,徐东平
DOI: https://doi.org/10.3969/j.issn.1672-5069.2009.01.005
2009-01-01
Abstract:Objective To investigate the occurrence of hepatitis B virus(HBV)precore/basal core promoter(BCP) mutations and its correlation on serum HBeAg expression in patients with chronic hepatitis B(CHB).Methods Sera were collected for extraction of HBV DNA.The precore/BCP gene fragment was amplified by an in-house nested PCR assay and analyzed by direct PCR-product sequencing.Based on reference literatures,6 mutation sites which possibly influencing HBeAg expression,secretion,or HBV replication were selected as follows:1753,1762,1764,1862,1896 and 1899.The data were processed by NTI software.Serum HBeAg was detected by enzyme-linked immunosorbent assay.Results Seventyfour(31.6%) of 234 patients enrolled in the study were mutation-negative at all 6 sites.Serum HBeAg positive rate of these cases was 74.3%.One hundred and sixty(68.4%) of the 234 patients were detected with various mutations at the sites,including 4 single-site and twenty-one multiple-site mutations.Among the total,73(31.2%) cases contained G1896A with or without coexistence of wild-type sequence at the sites,of whom 37 cases without coexistent wild-type sequence at the site had 18.9% HBeAg positive rate.Precore/BCP mutations other than G1896A were detected in 87 patients whose HBeAg positive rate was 63.2%(55/87).A1762T+G1764A was the most frequent mutation in patients positive with other than G1896A mutations,and the positive HBeAg was documented in 69.4%(34/49) of these patients.Four unusual substitutions were detected at site 1753 and 1862.Two cases were detected with insertion or deletion in precore/BCP region.Conclusion HBV precore/BCP mutations exist in most CHB patients in diverse forms.The patients with G1896A mutation had a significantly lower positive rate of serum HBeAg,while other mutations detected had little influence on HBeAgsecretion.Screening HBV precore/BCP mutations by DNA sequencing could obtain rich information and thus is valuable for evaluating disease progression and administrating anti-viral therapy in clinical practice.
What problem does this paper attempt to address?